Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Iterum Therapeutics, with a price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matthew Keller has given his Buy rating due to a combination of factors surrounding Iterum Therapeutics’ recent developments and strategic initiatives. The launch of ORLYNVAH, the first oral penem antibiotic in the U.S., positions the company uniquely in the market, especially given the rising issue of antibiotic resistance in urinary tract infections. This product addresses a significant unmet need, providing an effective treatment option for infections that have become increasingly resistant to existing medications.
Furthermore, Iterum’s strategic pre-commercialization activities, such as identifying regions with high resistance rates and developing comprehensive market access strategies, are expected to drive ORLYNVAH’s market penetration and sales growth. The company’s financial position, bolstered by recent funding, supports ongoing operations and further product development. These elements combined suggest a positive outlook for Iterum’s future performance, justifying the Buy rating.